rofecoxib has been researched along with Body Weight in 9 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, we examined the effect of various COX inhibitors on gastric ulcerogenic and acid secretory responses following daily exposure of the stomach to iodoacetamide (IA) and investigated the role for COX isozyme in gastric protection under subchronic mucosal irritation." | 3.72 | Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach. ( Hayashi, Y; Murakami, M; Takeeda, M; Takeuchi, K; Yamato, M, 2004) |
| "Quinolinic acid is an endogenous excitotoxin that causes neurotoxicity in diverse areas of the brain and produces motor dysfunction." | 1.36 | Protective effect of rofecoxib and nimesulide against intra-striatal quinolinic acid-induced behavioral, oxidative stress and mitochondrial dysfunctions in rats. ( Kalonia, H; Kumar, A; Kumar, P; Nehru, B, 2010) |
| "Quinolinic acid (QA) is a well-known excitotoxic agent that could induce behavioral, morphological and biochemical alterations similar with symptoms of Huntington's disease (HD), by stimulating NMDA receptors." | 1.35 | Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status. ( Kalonia, H; Kumar, A; Kumar, P; Nehru, B, 2009) |
| "In indomethacin and rofecoxib-treated gerbils, the following results were obtained in H pylori-infected group vs H pylori-eradicated group respectively: hyperplasia area of the stomach (mm2): 82." | 1.33 | Eradication of Helicobacter pylori significantly reduced gastric damage in nonsteroidal anti-inflammatory drug-treated Mongolian gerbils. ( Chang, CC; Chen, SH; Fang, CL; Hsieh, CR; Lien, GS; Lou, HY; Pan, S, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (88.89) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kalonia, H | 2 |
| Kumar, P | 2 |
| Kumar, A | 2 |
| Nehru, B | 2 |
| Schwartz, JI | 1 |
| Vandormael, K | 1 |
| Malice, MP | 1 |
| Kalyani, RN | 1 |
| Lasseter, KC | 1 |
| Holmes, GB | 1 |
| Gertz, BJ | 1 |
| Gottesdiener, KM | 1 |
| Laurenzi, M | 1 |
| Redfern, KJ | 1 |
| Brune, K | 1 |
| Höcherl, K | 1 |
| Endemann, D | 1 |
| Kammerl, MC | 1 |
| Grobecker, HF | 1 |
| Kurtz, A | 1 |
| Takeeda, M | 1 |
| Hayashi, Y | 1 |
| Yamato, M | 1 |
| Murakami, M | 1 |
| Takeuchi, K | 1 |
| Norflus, F | 1 |
| Nanje, A | 1 |
| Gutekunst, CA | 1 |
| Shi, G | 1 |
| Cohen, J | 1 |
| Bejarano, M | 1 |
| Fox, J | 1 |
| Ferrante, RJ | 1 |
| Hersch, SM | 1 |
| Chang, CC | 1 |
| Chen, SH | 1 |
| Lien, GS | 1 |
| Lou, HY | 1 |
| Hsieh, CR | 1 |
| Fang, CL | 1 |
| Pan, S | 1 |
| Jia, Q | 1 |
| Pestka, JJ | 1 |
| Fei, SJ | 1 |
| Xiao, SD | 1 |
| Peng, YS | 1 |
| Chen, XY | 1 |
| Shi, Y | 1 |
1 trial available for rofecoxib and Body Weight
| Article | Year |
|---|---|
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
Topics: Aged; Aged, 80 and over; Blood Pressure; Body Weight; Celecoxib; Creatinine; Cyclooxygenase Inhibito | 2002 |
8 other studies available for rofecoxib and Body Weight
| Article | Year |
|---|---|
Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status.
Topics: Animals; Body Weight; Caffeic Acids; Corpus Striatum; Cyclooxygenase 2 Inhibitors; Disease Models, A | 2009 |
Protective effect of rofecoxib and nimesulide against intra-striatal quinolinic acid-induced behavioral, oxidative stress and mitochondrial dysfunctions in rats.
Topics: Animals; Ataxia; Body Weight; Cell Survival; Corpus Striatum; Cyclooxygenase 2 Inhibitors; Lactones; | 2010 |
Cyclo-oxygenase-2 inhibition increases blood pressure in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Actins; Aldosterone; Animals; Anti-Inflammatory Agents, Non-Steroidal; | 2002 |
Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach.
Topics: Administration, Oral; Animals; Body Weight; Capsaicin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyg | 2004 |
Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice.
Topics: Acoustic Stimulation; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; As | 2004 |
Eradication of Helicobacter pylori significantly reduced gastric damage in nonsteroidal anti-inflammatory drug-treated Mongolian gerbils.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Chronic Diseas | 2005 |
Role of cyclooxygenase-2 in deoxynivalenol-induced immunoglobulin a nephropathy.
Topics: Analysis of Variance; Animals; Body Weight; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxyg | 2005 |
Chemopreventive effects of rofecoxib and folic acid on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Body Weight; Cell Proliferation; Folic Acid; Gastr | 2006 |